# EDGAR Filing Document

**Accession Number:** 0001778922
**File Stem:** 0001193125-26-045028
**Filing Date:** 2026-2
**Character Count:** 13123
**Document Hash:** f4cbdbccd5099a09208e2f866d0ab15b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-045028.hdr.sgml**: 20260210

**ACCESSION NUMBER**: 0001193125-26-045028

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260209

**FILED AS OF DATE**: 20260210

**DATE AS OF CHANGE**: 20260210

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Nielsen Kirk G.
- **CENTRAL INDEX KEY:** 0001523522

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43105
- **FILM NUMBER:** 26617606

**BUSINESS ADDRESS:**
- **BUSINESS PHONE:** 650-233-7877

**MAIL ADDRESS:**
- **STREET 1:** ONE SANSOME STREET
- **STREET 2:** SUITE 3630
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94104
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Klein Peter Justin
- **CENTRAL INDEX KEY:** 0001608710

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43105
- **FILM NUMBER:** 26617609

**MAIL ADDRESS:**
- **STREET 1:** 5425 WISCONSIN AVE
- **CITY:** CHEVY CHASE
- **STATE:** MD
- **ZIP:** 20815
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Vensana Capital I GP, LLC
- **CENTRAL INDEX KEY:** 0001854073

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43105
- **FILM NUMBER:** 26617608

**BUSINESS ADDRESS:**
- **STREET 1:** 3601 W 76TH ST
- **STREET 2:** SUITE 20
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55435
- **BUSINESS PHONE:** 650-843-5000

**MAIL ADDRESS:**
- **STREET 1:** 3601 W 76TH ST
- **STREET 2:** SUITE 20
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55435
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Vensana Capital I, L.P.
- **CENTRAL INDEX KEY:** 0001757539

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43105
- **FILM NUMBER:** 26617607

**BUSINESS ADDRESS:**
- **STREET 1:** 3601 W 76TH STREET
- **STREET 2:** SUITE 20
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55344
- **BUSINESS PHONE:** (650) 843-5000

**MAIL ADDRESS:**
- **STREET 1:** 3601 W 76TH STREET
- **STREET 2:** SUITE 20
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55344

**FORMER NAME:**
- **FORMER CONFORMED NAME:** VMT Fund I, L.P.
- **DATE OF NAME CHANGE:** 20181116

**FORMER NAME:**
- **FORMER CONFORMED NAME:** VMT I, L.P.
- **DATE OF NAME CHANGE:** 20181030
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SpyGlass Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001778922
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 833044245
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 27081 ALISO CREEK ROAD
- **STREET 2:** SUITE 125
- **CITY:** ALISO VIEJO
- **STATE:** CA
- **ZIP:** 92656
- **BUSINESS PHONE:** 949-284-6904

**MAIL ADDRESS:**
- **STREET 1:** 27081 ALISO CREEK ROAD
- **STREET 2:** SUITE 125
- **CITY:** ALISO VIEJO
- **STATE:** CA
- **ZIP:** 92656

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SpyGlassPharma, Inc.
- **DATE OF NAME CHANGE:** 20230711

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SpyGlass Ophthalmics, Inc.
- **DATE OF NAME CHANGE:** 20190605

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Vensana Capital I GP, LLC<br><sub>(Last) (First) (Middle)</sub><br>3601 W. 76TH STREET, SUITE 20<br><sub>(Street)</sub><br>EDINA, MN 55435<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-09 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>SpyGlass Pharma, Inc. [ SGP ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Vensana Capital I, L.P.<br><sub>(Last) (First) (Middle)</sub><br>3601 W. 76TH STREET, SUITE 20<br><sub>(Street)</sub><br>EDINA, MN 55435<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-09 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>SpyGlass Pharma, Inc. [ SGP ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Nielsen Kirk G.<br><sub>(Last) (First) (Middle)</sub><br>3601 W. 76TH STREET, SUITE 20<br><sub>(Street)</sub><br>EDINA, MN 55435<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-09 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>SpyGlass Pharma, Inc. [ SGP ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Klein Peter Justin<br><sub>(Last) (First) (Middle)</sub><br>3601 W. 76TH STREET, SUITE 20<br><sub>(Street)</sub><br>EDINA, MN 55435<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-09 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>SpyGlass Pharma, Inc. [ SGP ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-09 |  | C |  | 1690230 | A | <sup>(1)</sup> | 1690230 | I | See footnote<sup>(2)</sup> |
| Common Stock | 2026-02-09 |  | C |  | 548067 | A | <sup>(1)</sup> | 2238297 | I | See footnote<sup>(2)</sup> |
| Common Stock | 2026-02-09 |  | C |  | 548067 | A | <sup>(1)</sup> | 2786364 | I | See footnote<sup>(2)</sup> |
| Common Stock | 2026-02-09 |  | C |  | 359255 | A | <sup>(1)</sup> | 3145619 | I | See footnote<sup>(2)</sup> |
| Common Stock | 2026-02-09 |  | P |  | 165000 | A | $16.00 | 3310619 | I | See footnote<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series B Preferred Stock | <sup>(1)</sup> | 2026-02-09 |  | C |  |  | 9689922 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 1690230 | <sup>(1)</sup> | 0 | I | See Footnote<sup>(2)</sup> |
| Series C-1 Preferred Stock | <sup>(1)</sup> | 2026-02-09 |  | C |  |  | 3142015 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 548067 | <sup>(1)</sup> | 0 | I | See Footnote<sup>(2)</sup> |
| Series C-2 Preferred Stock | <sup>(1)</sup> | 2026-02-09 |  | C |  |  | 3142015 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 548067 | <sup>(1)</sup> | 0 | I | See Footnote<sup>(2)</sup> |
| Series D Preferred Stock | <sup>(1)</sup> | 2026-02-09 |  | C |  |  | 2059573 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 359255 | <sup>(1)</sup> | 0 | I | See Footnote<sup>(2)</sup> |

---

### Footnotes:

(1) Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

(2) These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

**Signature:** /s/ Steven Schwen, Chief Financial Officer of Vensana Capital I GP, LLC  
**Date:** 2026-02-10

**Signature:** /s/ Steven Schwen, Chief Financial Officer of Vensana Capital I GP, LLC, the general partner of Vensana Capital I, L.P.  
**Date:** 2026-02-10

**Signature:** /s/ Steven Schwen, as attorney-in-fact for Kirk Nielsen  
**Date:** 2026-02-10

**Signature:** /s/ Steven Schwen, as attorney-in-fact for Peter Justin Klein  
**Date:** 2026-02-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**